Omega-3 Fatty Acid Supplementation Decreases Liver Fat Content in Polycystic Ovary Syndrome:
Context:
There is an association between non-alcoholic fatty liver disease (NAFLD) and the polycystic ovary syndrome (PCOS).
Marine derived omega-3 fatty acids have favourable effects on cardiovascular risk, and could reduce liver fat in NAFLD.

Objective:
The primary aim of this study was to examine the effects of omega-3 fatty acids on liver fat in PCOS.
The secondary aim was to assess their effects on traditional cardiovascular risk factors.

Subjects:
25 women with PCOS (mean age 32.7 yr, mean body mass index 34.8 kg/m2).

Intervention:
Comparison of 4g/day of omega-3 fatty acids with placebo over 8 weeks.

Main outcome measures:
The primary outcome measure was hepatic fat content quantified using proton magnetic resonance spectroscopy.
Secondary outcome measures included fasting lipids and blood pressure.

Results:
Omega-3 fatty acids significantly decreased liver fat content compared with placebo

There was also a reduction in triglycerides systolic blood pressure and diastolic blood pressure with omega-3 fatty acids compared with placebo.

Omega-3 fatty acids particularly decreased hepatic fat in women with hepatic steatosis, defined as percentage liver fat

Conclusions:
Omega-3 fatty acid supplementation has a beneficial effect on liver fat content and other cardiovascular risk factors in women with PCOS, including those with hepatic steatosis.
Whether this translates into a reduction in cardiometabolic events warrants further study.

Subjects were randomized to 4 g daily of omega-3 fatty acids (4  1000-mg capsules of 56% docosahexaenoic acid and 27% eicosapentaenoic acid,

560+270=830 X 4 = 3320 mg omega 3. (equivalent to 10 standard grade fish oil capsules)

This Max DHA is about the same ratio of DHA to EPA they used you would need about 2.5 teaspoons daily.

This study demonstrates beneficial effects of omega-3 fatty acids on NAFLD
and additional markers of cardiometabolic risk in young, obese women with PCOS.The long-term cardioprotective effects of omega-3 fatty acids are now well accepted, and the findings of the current study suggest that women with PCOS are also likely to experience these benefits, although confirmation of these results in larger studies is required.
In the interim,management of women with PCOS should be guided by current recommendations that incorporate omega-3 fatty acids as part of a multifaceted approach to managing cardiometabolic risk.